Share

Save

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

PHASE3RECRUITING

This is a 12-month, parallel treatment, Phase 3, double-blind, randomized, placebo controlled study to evaluate the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in participants ≥16 years of age with Fabry disease who are treatment-naïve or untreated for at least 6 months. * Study visits will take place approximately every 3 months. * The double-blind period will be followed by an open-label extension (OLE) during which participants who have completed the double-blind period will be treated with venglustat for up to an additional 12 months.

info
Simpliy with AI

Study details:

Double blind period: the total duration will be up to approximately of 14 months (1 month of screening 12 month of treatment period, and a possible follow-up period of 1 month if no participation in the open label extension period). Open-label extension period: the total duration will be approximately of 31 months (12 month of OLE treatment, additional OLE treatment until a common study end of treatment date (CSEOTD, approximately 18 months), and 1 month of follow-up period).

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Male and female adult patients 16 year of age or older, who have had a previously confirmed diagnosis of Fabry disease and a history of clinical symptoms of Fabry disease
  • Patients who are treatment-naïve or without prior treatment with an approved or experimental therapy for Fabry disease within at least 6 months prior to screening.
  • Average score of ≥3 (0=no symptom, 10=symptom as bad as you can imagine) on the participant-defined most-bothersome symptom (among neuropathic pain in upper extremities, neuropathic pain in lower extremities, or abdominal pain), as measured by the Fabry Disease Patient-Reported Outcome (FD-PRO) at screening.
  • Contraception (with double contraception methods) for male and female participants; not pregnant or breastfeeding for female participants; no sperm donation for male participants.
  • Weight ≥30 Kg
  • A signed informed consent must be provided prior to any study-related procedures.
  • Exclusion criteria

  • Any manifestations of Fabry disease that preclude placebo administration.
  • History of transient ischemic attack, stroke, myocardial infarction, heart failure, evidence of left ventricular hypertrophy and/or cardiac fibrosis, major cardiovascular surgery, or kidney transplantation.
  • History of clinically significant cardiac arrhythmia. Atrial fibrillation that is well controlled on a stable medical regimen for at least 12 months is not an exclusion if the CHA2DS2-VASc score is 0 for males or 1 for females.
  • Patients with hepatitis C, HIV, or hepatitis B infection.
  • Neuropathic pain in upper or lower extremities, or abdominal pain not related to Fabry disease.
  • History of seizures currently requiring treatment.
  • Uncontrolled hypertension over the past 12 months prior to screening, or systolic BP >=150 or diastolic BP >=100 at screening.
  • Estimated glomerular filtration rate <60 mL/min/1.73m².
  • Urine protein to creatinine ratio >= 1 g/g at screening.
  • Presence of severe depression as measured by Beck's Depression Inventory (BDI)-II >28 and/or a history of an untreated, unstable major affective disorder within 1 year of the screening visit.
  • Positive SARS-CoV-2 virus test within 2 weeks of enrollment, or COVID 19 requiring hospitalization within 6 months of enrollment.
  • Moderate to severe hepatic impairment.
  • History of drug and/or alcohol abuse.
  • History of or active hepatobiliary disease.
  • Liver enzymes (alanine aminotransferase (ALT)/aspartate aminotransferase (AST)) or total bilirubin >2 times the upper limit of normal (ULN).
  • Initiation of chronic treatment for pain, or change in pain medication regimen, within 3 months prior to randomization.
  • Strong or moderate inducers or inhibitors of cytochrome P450 3A within 14 days or 5 half-lives, whichever is longer, prior to randomization.
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 16 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2022-03-11

    Primary completion: 2024-11-30

    Study completion finish: 2025-10-06

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE3

    trial

    Trial ID

    NCT05206773

    Intervention or treatment

    DRUG: Venglustat (GZ402671)

    DRUG: Placebo

    Conditions

    • Fabry Disease

    Find a site

    Closest Location:

    Investigational Site Number : 0360001

    Research sites nearby

    Select from list below to view details:

    • Investigational Site Number : 0360001

      Parkville, Victoria, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: Venglustat
    • Participant will receive venglustat dose once daily up to 12 months
    DRUG: Venglustat (GZ402671)
    • Pharmaceutical form: Tablet Route of administration: Oral
    PLACEBO_COMPARATOR: Placebo
    • Participants will receive placebo once daily up to 12 months
    DRUG: Placebo
    • Pharmaceutical form: Tablet Route of administration: Oral

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Percent change from baseline at 6 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, and abdominal pain)Not SpecifiedFrom baseline to 6 months
    Percent change from baseline at 12 months in the most bothersome symptom of 3 Fabry Disease Patient-Reported Outcome (FD-PRO) items (neuropathic pain in upper extremities, neuropathic pain in lower extremities, and abdominal pain)Not SpecifiedFrom baseline to 12 months

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Percent change in plasma globotriaosylsphingosine (lyso-GL-3)Not SpecifiedFrom baseline to 6 month and 12 months
    Frequency of rescue pain medication useNumber of days with use of rescue pain medications during the 6-month treatment period, divided by duration of the 6-month treatment period and multiplied by 100. The same definition will be used for the 12-month period.From baseline to 6 months and 12 months
    Change in the percentage of days with at least 1 stool reflecting diarrhea (Bristol Stool Form Scale [BSFS] Type 6 or 7)Not SpecifiedFrom baseline to 6 month and 12 months
    Percent change in tiredness component of FD-PRONot SpecifiedFrom baseline to 6 month and 12 months
    Proportion of responders in neuropathic or abdominal pain, as assessed by FD-PROResponse is defined as at least a 30% decrease from baseline in the most bothersome of 3 FD-PRO items between neuropathic pain in upper extremities, neuropathic pain in lower extremities, and abdominal painAt 6 months and 12 months
    Number of participants with adverse event (AE) and serious adverse event (SAE)Not SpecifiedFrom baseline to 6 month and 12 months
    Change in the lens clarity (new or worsening lens opacities) by ophthalmological examination (by slit lamp exam at Visit 2 and Visit 6)Not SpecifiedFrom baseline to 12 months
    Change in Beck Depression Inventory-II (BDI-II) scoreNot SpecifiedFrom baseline to 6 month and 12 months
    Plasma venglustat concentrations at prespecified visits over the study durationNot SpecifiedFrom baseline to 6 month and 12 months
    Maximum venglustat plasma concentration (Cmax)Not SpecifiedFrom baseline to 6 month and 12 months
    Time to maximum venglustat plasma concentration (tmax)Not SpecifiedFrom baseline to 6 month and 12 months
    Area under the venglustat plasma concentration versus time curve from time 0 to 24 hours (AUC0-24)Not SpecifiedFrom baseline to 6 month and 12 months

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

    Other trails to consider

    Top searched conditions